Lauren Silvis To Depart US FDA, Adding To High-Level String Of Agency Turnover In 2019
Lauren Silvis will leave her post as chief of staff at the US FDA in the next several weeks, when she will be replaced by associate commissioner for strategic initiatives and external affairs Keagan Lenihan.
You may also be interested in...
Long-time deputy John Farley becomes acting director of the Office of Antimicrobial Products. Cox, who served as the director of the office for more than a decade, joins Regeneron to serve as vice president of regulatory affairs.
FDA's inter-agency drug shortage task force wants comments on whether new shortage prevention and mitigation policies should include closer examination of mergers and acquisitions that could create drug shortages.
FDA’s latest drug shortages task force aims to encourage investment in the reliable manufacture of generic sterile injectables that are fundamental to the practice of medicine. While the agency’s first task force continues to work with industry to avert shortages, the second will strike at underlying structural issues that cause persistent shortages of these critical medicines.